Adcetris Tk (Brentuximab Vendotin Vials) 50mg

Brentuximab Vedotin works by targeting the CD30 protein found on the surface of certain cancer cells. The monoclonal antibody component binds to CD30, and once internalized, the monomethyl auristatin E (MMAE) component is released. MMAE disrupts the cell's microtubules, leading to cell cycle arrest and apoptosis, thereby killing the cancer cells.

The dose of Adcetris Tk is determined by a healthcare professional based on the patient's condition and response to treatment. It is typically administered as an intravenous infusion every three weeks, but the exact dosage and schedule should be determined by the prescribing physician.

Adcetris Tk should be avoided during pregnancy due to potential risks to the fetus. It is also recommended to avoid breastfeeding while using this medication. Patients should consult their healthcare provider for personalized advice.

To order Adcetris Tk from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the necessary import paperwork.

Adcetris Tk is a targeted therapy that specifically binds to CD30-positive cancer cells, minimizing damage to healthy cells. Compared to traditional chemotherapy, it may have a different side effect profile and may be more effective in certain types of lymphoma. The choice of treatment depends on the patient's specific condition and response to therapy.

Adcetris Tk should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. Proper storage and handling are crucial to maintain the medication's efficacy and safety. Always follow the storage instructions provided by the manufacturer.

Adcetris Tk is administered as an intravenous infusion by a healthcare professional. The infusion typically takes about 30 minutes, and the frequency of administration is determined by the prescribing physician based on the patient's condition and response to treatment.

The most serious risks associated with Adcetris Tk include severe infections, neutropenia, anemia, thrombocytopenia, severe allergic reactions, progressive multifocal leukoencephalopathy (PML), and peripheral neuropathy leading to severe disability. Patients should be closely monitored for these risks during treatment.

Adcetris Tk should not be used by patients who are allergic to Brentuximab Vedotin or any of its components. It should also be avoided during pregnancy and breastfeeding. Patients with certain medical conditions or those taking specific medications that interact with Adcetris Tk should consult their healthcare provider before starting treatment.